Osteotropic effects by the neuropeptides calcitonin gene-related peptide, substance P and vasoactive intestinal peptide

Journal of Musculoskeletal Neuronal Interactions

Volumn 8, Issue 2, 2008, Pages 154-165

  Lerner, Ulf H ^a   Persson, E ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

CGRP; Osteoblasts; Osteoclasts; SP; VIP

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; NEUROPEPTIDE; SUBSTANCE P; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTHRITIS; BONE DESTRUCTION; BONE EROSION; BONE MASS; BONE METABOLISM; BONE MINERALIZATION; BONE REMODELING; CARTILAGE DEGENERATION; ENDOPROSTHESIS LOOSENING; FRACTURE HEALING; GENE EXPRESSION; HUMAN; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; REVIEW;

ANIMALS; BONE AND BONES; BONE RESORPTION; CALCITONIN GENE-RELATED PEPTIDE; HUMANS; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; PARACRINE COMMUNICATION; SUBSTANCE P; VASOACTIVE INTESTINAL PEPTIDE;

EID: 51749102411     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000;100:197-207.
2. Takeda S, Elefteriou F, Lavasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002;111:305-17.
3. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo H, Richards WG, Bannon TW, Noda M, Clement K, Vaisse C, Karsenty G. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005;434:514-20.
4. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreuz C, Dacquin R, Mee PJ, McKee MD, Jung DJ, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G. Endocrine regulation of energy metabolism by the skeleton Cell 2007;130:456-69.
5. Baldock PA, Sainsbury A, Couzens M, Enriquez RF, Thomas GP, Gardiner EM, Herzog H. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 2002;109:915-21.
6. Lerner UH. Persson E. Lundberg P. Kinins and neuroosteogenic factors. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of Bone Biology, 3rd edition. San Diego: Academic Press; 2007 (in press).
7. Bjurholm A, Kreicbergs A, Brodin E, Schultzberg M. Substance P- and CGRP-immunoreactive nerves in bone. Peptides 1988;9:165-71.
8. Hill EL, Elde R. Distribution of CGRP-, VIP-, D betā H-, SP-, and NPY-immunoreactive nerves in the periosteum of the rat. Cell Tissue Res 1991;264:469-80.
9. Hukkanen M, Konttinen YT, Rees G, Santavirta S, Terenghi G, Polak JM. Distribution of nerve endings and sensory neuropeptides in rat synovium, meniscus and bone. Int J Tissue React 1992;14:1-10.
10. Dénes A, Boldogkoi Z, Hornyák A, Palkovits M, Kovács KJ. Attenuated pseudorabies virus-evoked rapid innate immune response in the rat brain. J Neuroimmunol 2005;180:88-103.
11. Hukkanen M, Konttinen YT, Santavirta S, Paavolainen P, Gu XH, Terenghi G, Polak JM. Rapid proliferation of calcitonin gene-related peptide-immunoreactive nerves during healing of rat tibial fracture suggests neuronal involvement in bone growth and remodelling. Neuroscience 1993;54:969-79.
12. Li J, Kreicbergs A, Bergström J, Stark A, Ahmed M. Site-specific CGRP innervation coincides with bone formation during fracture healing and modeling: a study in rat angulated tibia. J Orthop Res 2007; 25:1204-12.
13. Lerner UH. Deletions of the genes encoding calcitonin/a-CGRP, amylin and calcitonin receptor have given new and unexpected insights into the function of calcitonin receptors and calcitonin receptor-like receptors in bone. J Musculoskelet Neuronal Interact 2006;6:87-95.
14. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, Foord SM. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin and calcitonin receptors. Pharmacol Rev 2002;54:233-46.
15. Granholm S, Lundberg P, Lerner UH. Expression of the calcitonin receptor, calcitonin receptor-like receptor and receptor activity modifying proteins during osteoclast differentiation. J Cell Biochem 2008;104:920-33.
16. Nakamura M, Morimoto S, Yang Q, Hisamatsu T, Hanai N, Nakamura Y, Mori I, Kakudo K. Osteoclast-like cells express receptor activity modifying protein 2: application of laser capture microdissection. J Mol Endocrinol 2005;34:257-61.
17. Tippins JR, Morris HR, Panico M, Etienne T, Bevis P, Girgis S, MacIntyre I, Azria M, Attinger M. The myotropic and plasma calcium-modulating effects of calcitonin gene-related peptide (CGRP). Neuropeptides 1984;4:425-34.
18. Roos BA, Fischer JA, Pignaat W, Alander CB, Raisz LG. Evaluation of the in vivo and in vitro calcium-regulating actions of noncalcitonin peptides produced via calcitonin gene expression. Endocrinology 1986;118:45-51.
19. D'Souza SM, MacIntyre I, Girgis SI, Mundy GR. Human synthetic calcitonin gene-related peptide inhibits bone resorption in vitro. Endocrinology 1986;119:58-66.
20. Tamura T, Miyaura C, Owan I, Suda T. Mechanism of action of amylin on bone. J Cell Physiol 1992;153:6-14.
21. Yamamoto I, Kitamura N, Aoki J, Shigeno C, Hino M, Asonuma K, Torizaka K, Fujii N, Otaka A, Yajima H. Human calcitonin gene-related peptide possesses weak inhibitory potency of bone resorption in vitro. Calcif Tissue Int 1986;38:339-41.
22. Granholm S, Lerner UH. The members of the calcitonin gene family of peptides, including recently discovered intermedin and CRSP, inhibit both osteoclast activity and formation. J Bone Miner Res 2006; 21(Suppl.1):S364.
23. 37). Biochem Biophys Res Commun 1991;179:134-9.
24. Alam AS, Moonga BS, Bevis PJ, Huang CL, Zaidi M. Amylin inhibits bone resorption by a direct effect on the motility of rat osteoclasts. Exp Physiol 1992;78:183-96.
25. 2+ mobilization and cell retraction. J Endocrinol 1992;136:7-15.
26. Owan I, Ibaraki K. The role of calcitonin gene-related peptide (CGRP) in macrophages: the presence of functional receptors and effects on proliferation and differentiation into osteoclast-like cells. Bone Miner 1994;24:151-64.
27. Akopian A, Demulder A, Ouriaghli F, Corazza F, Fondu P, Bergmann P. Effects of CGRP on human osteoclast-like cell formation: a possible connection with the bone loss in neurological disorders? Peptides 2000;21:559-64.
28. Cornish J, Callon KE, Bava U, Kamona SA, Cooper GJS, Reid IR. Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. Bone 2001;29:162-8.
29. Ibbotson KJ, Roodman GD, McManus LM, Mundy GR. Identification and characterization of osteoclast-like cells and their progenitors in cultures of feline mononuclear cells. J Cell Biol 1984;99:471-80.
30. Roodman GD, Ibbotson KJ, MacDonald BR, Kuehl TJ. Mundy GR. 1,25-dihydroxyvitamin D3 causes formation of multinucleated cells with several osteoclast characteristics in cultures of primate marrow. Proc Natl Acad Sci USA 1985;82:8213-7.
31. Granholm S, Lundberg P, Lerner UH. Calcitonin inhibits osteoclast formation independently on transcriptional regulation by RANK and c-Fms. J Endocrinol 2007;195:415-27.
32. Hoff AO, Catala-Lehnen P, Thomas PM, Priemel M, Rueger JM, Nasonkin I, Bradley A, Hughes MR, Ordonez N, Cote GJ, Amling M, Gagel GF. Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J Clin Invest 2002;110:1849-57.
33. Schinke T, Liese S, Priemel M, Haberland M, Schilling AF, Catala-Lehnen P, Blicharski D, Rueger JM, Gagel RF, Emeson RB, Amling M. Decreased bone formation and osteopenia in mice lacking α-calcitonin gene-related peptide. J Bone Miner Res 2004;19:2049-56.
34. Dacquin R, Davey RA, Laplace C, Levasseur R, Morris HA, Goldring SR, Gebre-Medhin S, Galson DL, Zajac JD, Karsenty G. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J Cell Biol 2004;164:509-14.
35. Woodrow JP, Sharpe CJ, Fudge NJ, Hoff AO, Gagel RF, Kovacs CS. Calcitonin plays a critical role in regulating skeletal mineral metabolism during lactation. Endocrinology 2006;147:4010-21.
36. Michelangeli VP, Findlay DM, Fletcher A, Martin TJ. Calcitonin gene-related peptide (CGRP) acts independently of calcitonin on cyclic AMP formation in clonal osteogenic sarcoma cells (UMR 106-01). Calcif Tissue Int 1986;39:44-8.
37. Michelangeli VP, Fletcher AE, Allan EH, Nicholson GC, Martin TJ. Effects of calcitonin gene-related peptide on cyclic AMP formation in chicken, rat, and mouse bone cells. J Bone Miner Res 1989;4:269-72.
38. Thiebaud D, Akatsu T, Yamashita T, Suda T, Noda T, Martin RE, Fletscher AE, Martin TJ. Stucture-activity relationships in calcitonin gene-related peptide: cyclic AMP response in a preosteoblast cell line (KS-4). J Bone Miner Res 1991;6:1137-42.
39. Bjurholm A, Kreicbergs A, Schultzberg M, Lerner UH. Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR 106-01, ROS 17/2.8, MC3T3-E1, and Saos-2) and primary bone cells. J Bone Miner Res 1992;7:1011-9.
40. Pondel M. Calcitonin and calcitonin receptors: bone and beyond. Int J Exp Pathol 2000;81:405-22.
41. Uzan B, de Vernejoul MC, Cressent M. RAMPs and CRLR expressions in osteoblastic cells after dexamethasone treatment. Biochem Biophys Res Commun 2004;321:802-8.
42. Cornish J, Callon KE, Lin CQ, Xiao CL, Gamble GD, Cooper GJ, Reid IR. Comparison of the effects calcitonin gene-related peptide and amylin on osteoblasts. J Bone Miner Res 1999;14:1302-9.
43. Ballica R, Valentijn K, Khachatryan A, Guerder S, Kapadia S, Gundberg C, Gilligan J, Flavell RA, Vignery A. Targeted expression of calcitonin gene-related peptide to osteoblasts increases bone density in mice. J Bone Miner Res 1999;14:1067-74.
44. Offley SC, Guo TZ, Wei T, Clark JD, Vogel H, Lindsey DP, Jacobs CR, Yao W, Lane NE, Kingery WS. Capsaicin-sensitive sensory neurons contribute to the maintenance of trabecular bone integrity. J Bone Miner Res 2005;20:257-67.
45. Imai S, Matsusue Y. Neuronal regulation of bone metabolism and anabolism: calcitonin gene-related peptide-, substance P-, and tyrosine hydroxylase-containing nerves and the bone. Microsc Res Tech 2002;58:61-9.
46. Goto T, Tanaka T. Tachykinins and tachykinin receptors in bone. Microsc Res Tech 2002;58:91-7.
47. Liu D, Jiang LS, Dai LY. Substance P and its receptors in bone metabolism. Neuropeptides 2007;41:271-83.
48. Goto T, Yamaza T, Kido MA, Tanaka T. Light- and electron-microscopic study of the distribution of axons containing substance P and the localization of the neurokinin-1 receptor in bone. Cell Tissue Res 1998;293:87-93.
49. Togari A, Arai M, Mizutani S, Mizutani S, Koshihara Y, Nagatsu T. Expression of mRNAs for neuropeptide receptors and β-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells. Neurosci Lett 1997;233:125-8.
50. Shih C, Bernard GW. Neurogenic substance P stimulates osteogenesis in vitro. Peptides 1997;18:323-6.
51. Goto T, Nakao K, Gunjigake KK, Kido MA, Kobayashi S, Tanaka T. Substance P stimulates late-stage rat osteoblastic bone formation through neurokinin-1 receptors. Neuropeptides 2007;41:25-31.
52. Lundberg P, Lundgren I, Mukohyama H, Lehenkari PP, Horton MA, Lerner UH. Vasoactive intestinal peptide(VIP)/pituitary adenylate cyclase-activating peptide receptor subtype in mouse calvarial steoblasts: presence of VIP-2 receptors and differentiation-induced expression of VIP-1 receptors. Endocrinology 2001;142:339-47.
53. Azuma H, Kido J, Ikedo D, Kataoka M, Nagata T. Substance P enhances the inhibition of osteoblastic cell differentiation induced by lipopolysaccharide from Porphyromonas gingivalis. J Periodontol 2004;75:974-81.
54. Adamus MA, Dabrowski ZJ. Effect of the neuropeptide substance P on the rat bone marrow-derived osteogenic cells in vitro. J Cell Biochem 2001;81:499-506.
55. Mori T, Ogata T, Okumura H, Shibata T, Nakamura Y. Kataoka K. Substance P regulates the function of rabbit cultured osteoclasts; increase of intracellular free calcium concentration and enhancement of bone resorption. Biochem Biophys Res Commun 1999;262:418-22.
56. Sherman BE, Cole RA. A mechanism for sympathectomy-induced bone resorption in the middle ear. Otolaryngol Head Neck Surg 1995;113:569-81.
57. Sohn SJ. Substance P upregulates osteoclastogenesis by activating nuclear factor kappa B in osteoclast precursors. Acta Otolaryngol 2005;125:130-3.
58. Matayoshi T, Goto T, Fukuhara E, Takano H, Kobayashi S, Takahashi T. Neuropeptide substance P stimulates the formation of osteoclasts via synovial fibroblastic cells. Biochem Biophys Res Commun 2005;327:756-64.
59. Liu D, Li H, Zhao CQ, Jiang LS, Dai LY. Changes of substance P-immunoreactive nerve fiber innervation density in the sublesional bones in young growing rats at an early stage after spinal cord injury. Osteoporos Int 2007;19:559-69.
60. Wedemeyer C, Neuerburg C, Pfeiffer A, Heckelei A, von Knoch F, Hilken G, Brankamp J, Hensche F, von Koch M, Löer F, Saxler G. Polyethylene particle-induced bone resorption in substance P-deficient mice. Calcif Tissue Int 2007;80:268-74.
61. Ahmed M, Bergström J, Lundblad H, Gillespie WJ, Kreiebergs A. Sensory nerves in the interface membrane of aseptic loose hip prosthesis. J Bone Joint Surg Br 1998;80:151-5.
62. Said SI, Mutt V. Long acting vasodilator peptide from lung tissue. Nature 1969;224:699-700.
63. Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 1970;169:1217-8.
64. Said SI, Mutt V. Isolation from porcine-intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon. Eur J Biochem 1972;28:199-204.
65. Bodanszky M, Klausner YS, Said SI. Biological activities of synthetic peptides corresponding to fragments of and to the entire sequence of the vasoactive intestinal peptide. Proc Natl Acad Sci USA 1973;70:382-4.
66. Mutt V, Said SI. Structure of the porcine vasoactive intestinal octacosapeptide. The amino-acid sequence. Use of kallikrein in its determination. Eur. J Biochem 1974;42:581-9.
67. Said SI, Rosenberg RN. Vasoactive intestinal polypeptide: abundant immunoreactivity in neural cell lines and normal nervous tissue. Science 1976;192:907-8.
68. Brenneman DE, Hauser J, Philips TM, Davidson A, Bassan M, Gozes I. Vasoactive intestinal peptide. Link between electrical activity and glial-mediated neurotrophism. Ann NY Acad Sci 1999;897:17-26.
69. Blondel O, Collin C, McCarran WJ, Zhu S, Zamostiano R, Gozes I, Brenneman DE, McKay RD. A glia-derived signal regulating neuronal differentiation. J Neurosci 2000;20:8012-20.
70. Groneberg DA, Rabe KF, Fischer A. Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal peptide and its receptors. Eur J Pharmacol 2006;533:182-94.
71. Henning RJ, Sawmiller DR. Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc Res 2001; 49:27-37.
72. Cooke HJ. Neurotransmitters in neuronal reflexes regulating intestinal secretion. Ann NY Acad Sci 2000;915:77-80.
73. van Geldre LA, Lefebvre RA. Interaction of NO and VIP in gastrointestinal smooth muscle relaxation. Curr Pharm Des 2004;10:2483-97.
74. Fahrenkrug J. Gut/brain peptides in the genital tract: VIP and PACAP. Scand J Clin Lab Invest Suppl 2001;234:35-9.
75. Voice JK, Dorsam G, Chan RC, Grinninger C, Kong Y, Goetzl EJ. Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide. Regul Pept 2002;109:199-208.
76. Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 2004;56:249-90.
77. Gozes I, Furman S. Clinical endocrinology and metabolism. Potential clinical applications of vasoactive intestinal peptide: a selected update. Best Pract Res Clin Endocrinol Metab 2004;18:623-40.
78. Hohmann EL, Elde RP, Rysavy JA, Einzig S, Gebhard RL. Innervation of periosteum and bone by sympathetic vasoactive intestinal peptide-containing fibers. Science 1986;232:868-71.
79. Bjurholm A, Kreicbergs A, Terenius L, Goldstein M, Schultzberg M. Neuropeptide Y-, tyrosine hydroxylase, and vasoactive intestinal peptide-immunoreactive nerves in bone and surrounding tissues. J Autonom Nerv Syst 1988;25:119-25.
80. Segre GV, Goldring SR. Receptors for secretin, calcitonin, parathyroid hormone (PTH)/PTH-related peptide, vasoactive intestinal peptide, glucagonlike peptide 1, growth hormone-releasing hormone, and glucagon belong to a newly discovered G-protein-linked receptor family. Trends Endocrinol Metab 1993;4:309-14.
81. Laburthe M, Couvineau A. Molecular pharmacology and structure of VPAC receptors for VIP and PACAP. Regul Pept 2002;108:165-73.
82. Usdin TB, Bonner TI, Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 1994;135:2662-79.
83. Hohmann EL, Levine L, Tashjian AH Jr. Vasoactive intestinal peptide stimulates bone resorption via a cyclic adenosine 3′5′-monophosphate-dependent mechanism. Endocrinology 1983;112:1233-9.
84. Hohmann EL, Tashjian AH Jr. Functional receptors for vasoactive intestinal peptide on human osteosarcoma cells. Endocrinology 1984;114:1321-7.
85. Lerner UH, Lundberg P, Ransjö M, Persson P, Håkanson R. Helodermin, helospectin, and PACAP stimulate cyclic AMP formation in intact bone, isolated osteoblasts, and osteoblastic cell lines. Calcif Tissue Int 1994;54:284-9.
86. Kovacs CS, Chik CL, Li B, Karpinski E, Ho AK. Pituitary adenylate cyclase-activating peptide stimulates cyclic AMP accumulation in UMR 106 osteoblast-like cells. J Endocrinol 1996;149:287-95.
87. Susuki A, Kontoyori J, Oiso Y, Kozawa O. Pituitary adenylate cyclase-activating peptide induces cAMP production independently from vasoactive intestinal polypeptide in osteoblast-like cells. Cell Signal 1994;6:11-6.
88. Lundberg P, Lie A, Bjurholm A, Lehenkari PP, Horton MA, Lerner UH, Ransjö M. Vasoactive intestinal peptide regulates osteoclast activity via specific binding sites on both osteoclasts and osteoblasts. Bone 2000;27:803-10.
89. Ransjö M, Lie A, Mukohyama H, Lundberg P, Lerner UH. Microisolated mouse osteoclasts express VIP-1 and PACAP receptors. Biochem Biophys Res Commun 2000;274:400-4.
90. Lundberg P, Boström I, Mukohyama H, Bjurholm A, Smans K, Lerner UH. Neuro-hormonal control of bone metabolism: vasoactive intestinal peptide stimulates alkaline phosphatase activity and mRNA expression in mouse calvarial osteoblasts as well as calcium accumulation in mineralised bone nodules. Regul Pept 1999;85:47-58.
91. Mukohyama H, Ransjö M, Taniguchi H, Ohyama T, Lerner UH. The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. Biochem Biophys Res Commun 2000;271:158-63.
92. Cai Y, Xin X, Shim GJ, Mokuno Y, Uehara H, Yamada T, Agui T, Matsumo K. Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of VIP/PACAP receptor in rat bone marrow-derived cells. Endocrinology 1997;138:2515-20.
93. Greenfield EM, Horowitz MC, Lavish SA. Stimulation by parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts is an immediate-early gene response induced by cAMP signal transduction. J Biol Chem 1996;271:10984-9.
94. Persson E, Voznesensky OS, Huang YF, Lerner UH. Increased expression of interleukin-6 by vasoactive intestinal peptide is associated with regulation of CREB, AP-1, and C/EBP, but not of NF-B, in mouse calvarial osteoblasts. Bone 2005;37:513-29.
95. Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 2004;56:249-90.
96. Persson E, Lerner UH. The neuropeptide VIP potentiates IL-6 production induced by pro-inflammatory osteotropic cytokines in calvarial osteoblasts and the osteoblastic cell line MC3T3-E1. Biochem Biophys Res Commun 2005;335:705-11.
97. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP. Vasoactive intestinal peptide prevents experimental arthritis by down-regulating both autoimmune and inflammatory components of the disease. Nature Med 2001;7:563-8.
98. Juarranz Y, Abad C, Martinez C, Arranz A, Gutierrez-Cañas I, Rosignoli F, Gomariz RP, Leceta J. Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2005;7:R1034-45.